Navigation Links
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease

SAN DIEGO, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, Inc. today presented interim clinical data from a Phase 1 trial of CERE-110, a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. After one year of follow-up, the results for the six patients who received CERE-110 in the trial indicate that a single administration of the therapy was well tolerated, and an interim analysis suggested that the therapy had the potential to reduce the rate of cognitive decline and increase brain metabolism. These data were presented today by Zoe Arvanitakis, M.D., and David Bennett, M.D., co-principal investigators, Rush Alzheimer's Disease Center, Dept. of Neurological Sciences, Rush University Medical Center, at the American Academy of Neurology Meeting in Boston, Massachusetts.

The Phase 1 trial at Rush University Medical Center was a single-site, open-label study involving six patients with mild-to-moderate Alzheimer's disease and was conducted for the purpose of evaluating whether CERE-110-NGF administered by an adeno-associated viral gene delivery system-could be safely delivered. All six patients enrolled in the study underwent stereotactic neurosurgery to deliver CERE-110 into a specific region of the brain called the Nucleus Basalis of Meynert (NBM) -- an area that is a source for the production of cholinergic neurons, which are known to undergo profound degeneration in patients with Alzheimer's disease. The administration of CERE-110 was generally well tolerated.

The six patients underwent cognitive testing, and the data suggest that a reduction in the rate of cognitive decline may have been achieved. PET (positron emission tomography) scans were also obtained of the patients' brains at baseline, six and 12 months, and increases in brain metabolism were observed in several cortical regions at six months (p<0.05). Further increases in metabolism
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinsons Patients
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:9/3/2015)... 3, 2015 The report "Biocides ... acids, Phenolics, and Others) and by Application (Water treatment, ... coatings, and Others) - Global Trends and Forecasts to ... Market with an analysis and forecast for types and ... Browse   88 tables and   63 figures ...
(Date:9/2/2015)... 2, 2015 About Balloon ... one or more vertebral bodies, resulting in persistent ... bone disease, is a leading cause of VCF ... metastatic spinal tumors, and traumatic injuries also cause ... kyphoplasty to rectify the condition. Both procedures are ...
(Date:9/2/2015)... , Sept. 2, 2015  The report on ... market of breast cancer drugs on the basis of ... usually originates from the inner lining of milk ducts ... a malignant type of tumor that can spread to ... cancer which starts in lobules is referred as lobular ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5Global Balloon Kyphoplasty Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
...  "This is a significant decision in a case being ... entire pharmaceutical industry," commented Benjamin H. Anderson, Esq. "We ... hearing was not necessary and that the three-judge panel ... the diet drug Redux (commonly known as fen-phen) should ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... of cancer, today announced that it has received ... that it has regained compliance with the minimum ... requirement for continued listing on the NASDAQ Capital ...
Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
(Date:9/3/2015)... ... September 03, 2015 , ... The Linda Hall Library ... of a comet, the IceCube observatory at the South Pole, and the interior of ... Fall Lecture Series for the world's foremost independently funded research library devoted to science, ...
(Date:9/3/2015)... ... September 03, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Melissa ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:9/3/2015)... CANADA (PRWEB) , ... September 03, 2015 , ... ... today announced that it will be spotlighting its award-winning print and artwork inspection solutions, ... Vision team September 16 and 17 at the Olympia London, booth #F33 , Be ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, to their ... board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea ...
(Date:9/3/2015)... ... 03, 2015 , ... ProScrub is a set of automated tools that allow ... custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to ... are perfect complements to energetic video productions. ProScrub is a Final Cut ...
Breaking Medicine News(10 mins):Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... (About Euro 46 M),Frutarom Establishes its Position as One of the 10 Largest ... ... Frutarom Continues to Implement Rapid Growth Strategy, HAIFA, Israel, October ... it has signed an agreement to acquire 100% of the share capital of ...
... (October 15, 2007) Patients have on average a ... top-rated hospitals compared with the lowest-rated hospitals across 18 ... Hospital Quality in America Study, issued today by HealthGrades, ... wide variation in the quality of care between the ...
... A new study by Rhode Island Hospital and Brown University ... surgery did not receive the initial psychiatric clearance for the ... of decisions to clear candidates for surgery, and the largest ... and detail the reasons for exclusion. It was published in ...
... created an easy-to-produce material from the stuff of ... bend light in the opposite direction from all ... to significant advances in many areas, including high-speed ... A Princeton-led research team has created an easy-to-produce ...
... other vital organs is critical for survival, experts say, ... flow to the brain and other vital organs is ... emphasize chest compressions over rescue breathing, particularly for heart ... is just two breaths per every 30 chest compressions. ...
... in Support of National Breast ... Cure, DALLAS, Oct. 13 NASCAR drivers Bobby ... Cure at today,s Bank of,America 500 race at Lowe,s ... ) Bobby Labonte,s #43, sponsored by General Mills, ...
Cached Medicine News:Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 2Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 3Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 4Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 5Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 3Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 3Health News:Chest Compressions Key to Revised CPR Guidelines 2Health News:Chest Compressions Key to Revised CPR Guidelines 3Health News:General Mills' #43, M&M's #38 Driving Passionately Pink for the Cure at Lowe's Motor Speedway NASCAR Race 2
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
... The Inteq TFCC ... facilitates suturing of the ... the dorsal capsule when ... The Inteq system should ...
... Series I Small Joint ... features a complete line ... instruments specifically designed for ... are available in a ...
Medicine Products: